Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers May 26, 2017
Pharmacy Choice - News - U.S. Pharmaceutical Industry - May 26, 2017

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

4/26/17 - "N-Acetylglucosamine Sugar Chain Group-Containing Compound, Carrier Compound for Drug Delivery, Drug Preparation, and Drug Delivery System" in Patent...
"N-Acetylglucosamine Sugar Chain Group-Containing Compound, Carrier Compound for Drug Delivery, Drug Preparation, and Drug Delivery System" in Patent Application Approval Process. By a News Reporter-Staff News Editor at Biotech Week A patent application by the inventor ISE, Hirohiko, filed on May 19, 2015, was made available online on April 13, 2
4/26/17 - AcelRx Pharmaceuticals to Hold First Quarter 2017 Financial Results Conference Call and Webcast on Monday, May 8th, 2017
AcelRx Pharmaceuticals, Inc.,, a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that it will release First Quarter financial results after market close on Monday, May 8th, 2017. About AcelRx Pharmaceuticals, Inc. AcelRx..
4/26/17 - Aclaris Therapeutics Announces Notice of Allowance for a U.S. Patent Application Covering Lead Candidate A-101 Topical Solution
Aclaris Therapeutics, Inc., a dermatologist-led, biotechnology company focused on defining innovative therapies in medical and aesthetic dermatology, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for a patent application covering the formulation and methods of use of A-101 40% topica
4/26/17 - Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy, announced today the closing of its previously announced underwritten public offering of 4,285,715 shares of its common stock at a public offering price of $3.50..
4/26/17 - Alnylam Reports Final 24-Month Results from Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today final 24- month results from its Phase 2 open-label extension study of patisiran, an investigational RNAi therapeutic targeting transthyretin for the treatment of hATTR amyloidosis. These clinical data are being presented at the American Academy of Neurology 2017.
4/26/17 - AMAG Pharmaceuticals Appoints Arpad Simon, M.D. as Vice President of Pharmacovigilance [T-break Tech (Middle East)]
-AMAG Pharmaceuticals, Inc. today announced the appointment of Arpad Simon, M.D., to the role of vice president of pharmacovigilance. Dr. Simon has worked in the pharmaceutical industry for more than 20 years with extensive operational and leadership experience in clinical development and pharmacovigilance. In addition to his leading roles in the..
4/26/17 - AMAG Pharmaceuticals to Present at the Deutsche Bank Health Care Conference
AMAG Pharmaceuticals, Inc. today announced that management will participate in a fireside chat at the 42 nd Annual Deutsche Bank Health Care Conference on Wednesday, May 3, 2017 at 2:50 p.m. ET.. A live audio webcast will be accessible through the Investors section of the company s website at www.amagpharma.com, and will be archived for 30 day
4/26/17 - Analyzing Generics Market in Brazil 2017
Dublin- Research and Markets has announced the addition of the "Analyzing Generics Market in Brazil 2017" report to their offering. Brazil has a booming pharmaceutical market. The pharmaceutical industry in Brazil is the sixth biggest in the world in terms of value.
4/26/17 - Analyzing Generics Market in Brazil 2017 - Research and Markets
Research and Markets has announced the addition of the "Analyzing Generics Market in Brazil 2017" report to their offering. Brazil has a booming pharmaceutical market. The pharmaceutical industry in Brazil is the sixth biggest in the world in terms of value.
4/26/17 - ARCA biopharma Announces 200th Patient Randomized into the GENETIC-AF Seamless Design Phase 2B/3 Clinical Trial
ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that the 200 th patient has been randomized into the GENETIC-AF clinical trial evaluating Gencaro? as potentially the first genetically-targeted treatment for atrial...
4/26/17 - Arno Therapeutics is a biopharmaceutical company focused on creating value through the development of innovative products for the treatment of cancer patients.
Arno Therapeutics Parsippany, NJ, USBiotechnologywww.arnothera.com Arno Therapeutics is a biopharmaceutical company focused on creating value through the development of innovative products for the treatment of cancer patients. &am...
4/26/17 - Asterias Announces Publication of Positive Phase 2 Data on AST-VAC1 for the Treatment of Acute Myeloid Leukemia (AML) in 'Cancer'
Asterias Biotherapeutics, Inc., a biotechnology company focused on the emerging field of regenerative medicine, today announced that the results from its completed Phase 2 clinical trial of AST-VAC1 are now available online in Cancer, a leading peer-reviewed journal of the American Cancer Society. The study publication is available at...
4/26/17 - Bellicum Pharmaceuticals to Present at the Deutsche Bank 42nd Annual Health Care Conference
Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair, President and CEO, is scheduled to present a corporate overview at the Deutsche Bank 42nd Annual Health Care Conference on Wednesday, May 3 at 2:10 p.m. A live webcas
4/26/17 - BeyondSpring Enrolls First U.S. Patient in Phase 2/3 Clinical Trial of Plinabulin for Neutropenia Prevention [Tehran Times (Iran)]
-BeyondSpring Inc., a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company has enrolled the first patient at the Hematology/ Oncology Northshore, Illinois, in its Phase 2/ 3 study of BeyondSprings lead asset, Plinabulin, for the prevention of neutropenia, in comb
4/26/17 - Bharat Book Bureau: Global Radiopharmaceutical Market
Radiopharmaceuticals are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. This report focuses on the Radiopharmaceutical in Global market, especially in North America, Europe and Asia-Pacific, South Ame
4/26/17 - Biodel Inc. (Biodel) is a development-stage company. The Company is a biopharmaceutical company focused on the development and commercialization of treatments for diabetes.
It develops its product candidates by applying its formulation technologies to existing drugs. Its product candidate is Linjeta....
4/26/17 - Biomedical Systems Forms Strategic Partnership with RadMD
By a News Reporter-Staff News Editor at Biotech Week Biomedical Systems- an over 40- year-old, leading clinical trial provider to pharmaceutical, medical device, biotech, and contract research organizations announced a strategic partnership with RadMD, a global provider for independent expert physician image reviews for both safety and efficacy..
4/26/17 - BioPharmX Announces $5.0 Million Offering
BioPharmX Corporation, a specialty pharmaceutical company developing products for the dermatology market, announced that it is has entered into securities purchase agreements with certain existing institutional investors for the purchase and sale of 6,410,258 shares of common stock at a price of $0.78 per share with 50% warrant coverage in a...
4/26/17 - Boston Therapeutics Obtains Financing for International Trial
Boston Therapeutics announced the complete funding for a new phase II/III BTI320 trial on type 2 diabetic patients, in partnership with Advance Pharmaceutical Company Limited. Recruitment will initiate at the Joslin Diabetes Center, Boston, MA, and will be joined by its former trial center form the Chinese University of Hong Kong which has also bee
4/26/17 - Boston Therapeutics secures $1 Million financing for the first phase Multi-Centre International Ph II-III Trial
Boston Therapeutics, Inc. and its Asian partner Advance Pharmaceutical Company Limited, Hong Kong, announced today the fully financed new trial plans to support the safety and efficacy of BTI320, starting with a randomized, placebo-controlled, double-blinded, multi-center, international study on type 2 diabetic patients. Recruitment will initiate a
4/26/17 - Braeburn Pharmaceuticals Achieves Primary Endpoint in Pivotal Phase 2/3 Study of BB0817, Risperidone 6-month Implant for Treatment of Schizophrenia
Braeburn Pharmaceuticals announced today that a 6- month study of the safety, tolerability and pharmacokinetics of transferring patients diagnosed with schizophrenia or schizoaffective disorder and stabilized on oral risperidone to BB0817 implant has met its primary endpoint. The trial was designed to demonstrate comparable average plasma...
4/26/17 - Bristol-Myers Squibb and Apexigen, Inc. Announce Clinical Collaboration to Evaluate Opdivo nivolumab in Combination with APX005M in Advanced Solid...
Bristol-Myers Squibb and Apexigen, Inc. Announce Clinical Collaboration to Evaluate Opdivo nivolumab in Combination with APX005M in Advanced Solid Tumors. By a News Reporter-Staff News Editor at Biotech Week Bristol-Myers Squibb Company and Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing...
4/26/17 - Capricor Therapeutics to Present at the Alliance for Regenerative Medicine's Cell & Gene Therapy Investor Day
Capricor Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class biological therapies for cardiac and other medical conditions, today announced that Linda Marbn, Ph.D., president and chief executive officer, is scheduled to present at the Alliance for Regenerative Medicine's 5 th Annual Cell& Gene Therapy Investor D
4/26/17 - Clearside Biomedical, Inc. to Present at the Deutsche Bank 42nd Annual Health Care Conference
Clearside Biomedical, Inc., a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced today that its Chief Executive Officer and President, Daniel H. White, will present at the Deutsche Bank 42nd Annual Health Care Conference on Wednesday, May 3, 2017 at 4:10 p.m. ET at the...
4/26/17 - Coalition Duchenne Congratulates Capricor Therapeutics on Positive Six-Month Results from its Randomized CAP-1002 Phase I/II HOPE Clinical Trial in Duchenne [T-break Tech (Middle East)]
-Coalition Duchenne, a charity based in Newport Beach, California, committed to raising awareness for Duchenne muscular dystrophy, and funding for Duchenne research, congratulates Capricor Therapeutics on positive six-month results from its randomized CAP-1002 Phase I/II HOPE clinical trial in Duchenne announced today. Coalition Duchenne funded...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Telepharmacy- Remote Delivery of Pharmacy Services
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415